Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells

Cell Biology and Toxicology

Volumn 29, Issue 6, 2013, Pages 431-443

  Robles Escajeda, Elisa ^a   Martínez, Alberto ^b   Varela Ramirez, Armando ^a   Sánchez Delgado, Roberto A ^c   Aguilera, Renato J ^a  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b NEW YORK CITY COLLEGE OF TECHNOLOGY   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Apoptosis; Clotrimazole; Ketoconazole; Prostate cancer cell lines; Ruthenium

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CLOTRIMAZOLE; CLOTRIMAZOLE RUTHENIUM; KETOCONAZOLE; KETOCONAZOLE RUTHENIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG SELECTIVITY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; LYMPHOBLASTOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; UTERINE CERVIX CANCER;

APOPTOSIS; CELL LINE, TUMOR; CLOTRIMAZOLE; DNA, NEOPLASM; HUMANS; KETOCONAZOLE; MALE; PROSTATIC NEOPLASMS; RUTHENIUM;

EID: 84890799430     PISSN: 07422091     EISSN: 15736822     Source Type: Journal    
DOI: 10.1007/s10565-013-9264-z     Document Type: Article

References (73)

1. Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, et al. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br J Cancer. 2002;86(10):1652-7. (Pubitemid 34628122)
2. Anzelloti A. Study of possible mechanisms of action of ruthenium-azole complexes against Trypanosoma cruzi. Venezuelan Institute for Scientific Research (IVIC), Caracas, Venezuela; M.Sc. Thesis. 2004.
3. Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, et al. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther. 1999;289(1):559-64. (Pubitemid 29156075)
4. Berger MR, Garzon FT, Keppler BK, Schmahl D. Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats. Anticancer Res. 1989;9(3):761-5. (Pubitemid 19194313)
5. Bok RA, Small EJ. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf. 1999;20(5):451-8. (Pubitemid 29231659)
6. Borlak J, Thum T. Induction of nuclear transcription factors, cytochrome P450 monooxygenases, and glutathione S-transferase alpha gene expression in Aroclor 1254-treated rat hepatocyte cultures. Biochem Pharmacol. 2001;61(2):145-53. (Pubitemid 32121779)
7. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988;106:761-71. (Pubitemid 18089976)
8. Brabec V, Kleinwachter V, Butour JL, Johnson NP. Biophysical studies of the modification of DNA by antitumour platinum coordination complexes. Biophys Chem. 1990;35(2-3):129-41. (Pubitemid 20185433)
9. Bratsos I, Jedner S, Gianferrara T, Alessio E. Ruthenium anticancer compounds: challenges and expectations. Chimia. 2007a;61:692-7.
10. Bratsos I, Serli B, Zangrando E, Katsaros N, Alessio E. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity. Inorg Chem. 2007b;46(3):975-92.
11. Cao MY, Lee Y, Feng NP, Al-Qawasmeh RA, Viau S, Gu XP, et al. NC381, a novel anticancer agent, arrests the cell cycle in G0-G1 and inhibits lung tumor cell growth in vitro and in vivo. J Pharmacol Exp Ther. 2004;308(2):538-46. (Pubitemid 38134215)
12. Castonguay A, Doucet C, Juhas M, Maysinger D. New ruthenium(II)-letrozole complexes as anticancer therapeutics. J Med Chem. 2012;55(20):8799-806.
13. Cutts SM, Masta A, Panousis C, Parsons PG, Sturm RA, Phillips DR. A gel mobility shift assay for probing the effect of drug-DNA adducts on DNA-binding proteins. Methods Mol Biol. 1997;90:95-106.
14. De CR, Wouters W, Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol. 1996;56:133-43. (Pubitemid 26107887)
15. Dougan SJ, Melchart M, Habtemariam A, Parsons S, Sadler PJ. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity. Inorg Chem. 2006;45(26):10882-94.
16. Duret C, Daujat-Chavanieu M, Pascussi JM, Pichard-Garcia L, Balaguer P, Fabre JM, et al. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol. 2006;70(1):329-39.
17. Eichenberger T, Trachtenberg J, Chronis P, Keating A. Synergistic effect of ketoconazole and antineoplastic agents on hormone-independent prostatic cancer cells. Clin Invest Med. 1989a;12:363-6. (Pubitemid 20014985)
18. Eichenberger T, Trachtenberg J, Toor P, Keating A. Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J Urol. 1989; 141:190-1. (Pubitemid 19028867)
19. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73(4):1907-16. (Pubitemid 40470787)
20. Frasca D, Ciampa J, Emerson J, Umans RS, Clarke MJ. Effects of hypoxia and transferrin on toxicity and DNA binding of ruthenium antitumor agents in hela cells. Metal-Based Drugs. 1996;3(4):197-209. (Pubitemid 27026237)
21. Gallori E, Vettori C, Alessio E, Vilchez FG, Vilaplana R, Orioli P, et al. DNA as a possible target for antitumor ruthenium(III) complexes. Arch Biochem Biophys. 2000;376(1):156-62. (Pubitemid 30205125)
22. Garzon FT, Berger MR, Keppler BK, Schmahl D. Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats. Cancer Chemother Pharmacol. 1987;19(4):347-9. (Pubitemid 17133265)
23. Gong Y, Blok LJ, Perry JE, Lindzey JK, Tindall DJ. Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology. 1995;136(5):2172-8.
24. Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A, Berger W, et al. KP1019, a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers. 2008;5(10):2140-55.
25. Hegemann L, Toso SM, Lahijani KI, Webster GF, Uitto J. Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. J Invest Dermatol. 1993;100(3):343-6. (Pubitemid 23083196)
26. Ho YS, Tsai PW, Yu CF, Liu HL, Chen RJ, Lin JK. Ketoconazole-induced apoptosis through P53-dependent pathway in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol. 1998;153:39-47. (Pubitemid 28563888)
27. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983; 43:1809-1818. (Pubitemid 13122588)
28. Huang HL., Li ZZ, Liang ZH, Liu YJ. Cell cycle arrest, cytotoxicity, apoptosis, DNA-binding, photocleavage, and antioxidant activity of octahedral ruthenium(II) complexes. Eur J Inorg Chem, 2011; 2011:5538-5547.
29. Iniguez E, Sanchez A, Vasquez M, Martinez A, Olivas J, Sattler A, et al. Metal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells. J Biol Inorg Chem. 2013;18(7):779-90.
30. Ito C, Tecchio C, Coustan-Smith E, Suzuki T, Behm FG, Raimondi SC, et al. The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis. Leukemia. 2002; 16:1344-52.
31. Jakupec MA, Galanski M, Arion VB, Hartinger CG, Keppler BK. Antitumour metal compounds: more than theme and variations. Dalton Trans. 2008;2:183-94. (Pubitemid 350278321)
32. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 1999;99(9):2467-98.
33. Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, et al. Cell death: apoptosis versus necrosis (review). Int J Oncol. 2002;21(1):165-70.
34. Kapitza S, Pongratz M, Jakupec MA, Heffeter P, Berger W, Lackinger L, et al. Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. J Cancer Res Clin Oncol. 2005;131(2):101-10. (Pubitemid 40192935)
35. Kljun J, Bratsos I, Alessio E, Psomas G, Repnik U, Butinar M, et al. New uses for old drugs: attempts to convert quinolone antibacterials into potential anticancer agents containing ruthenium. Inorg Chem. 2013;52(15):9039-52.
36. Lema C, Varela-Ramirez A, Aguilera RJ. Differential nuclear staining assay for high-throughput screening to identify cytotoxic compounds. Curr Cell Biochem. 2011;1(1):1-14.
37. Lippert BE. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Verlag Helvetica Chimica Acta; 2006.
38. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011; 12:153-159.
39. Mac NS, Dawson RA, Crocker G, Tucker WF, Bittiner B, Singleton JG, et al. Antiproliferative effects on keratinocytes of a range of clinically used drugs with calmodulin antagonist activity. Br J Dermatol. 1993;128:143-50. (Pubitemid 23054331)
40. Martinez A, Rajapakse CS, Sanchez-Delgado RA, Varela-Ramirez A, Lema C, Aguilera RJ. Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells. J Inorg Biochem. 2010;104(9):967-77.
41. Martinez A, Carreon T, Iniguez E, Anzellotti A, Sanchez A, Tyan M, et al. Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in vitro activity against Leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells. J Med Chem. 2012; 55:3867-77.
42. Morbidelli L, Donnini S, Filippi S, Messori L, Piccioli F, Orioli P, et al. Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. Br J Cancer. 2003;88(9):1484-91. (Pubitemid 36608951)
43. Morris RE, Aird RE, Murdoch PS, Chen H, Cummings J, Hughes ND, et al. Inhibition of cancer cell growth by ruthenium(II) arene complexes. J Med Chem. 2001;44(22):3616-21. (Pubitemid 33026669)
44. Navarro M, Pena NP, Colmenares I, Gonzalez T, Arsenak M, Taylor P. Synthesis and characterization of new palladium-clotrimazole and palladium-chloroquine complexes showing cytotoxicity for tumor cell lines in vitro. J Inorg Biochem. 2006;100(1):152-7. (Pubitemid 43005027)
45. Navarro M, Highera-Padilla AR, Arsenak M, Taylor P. Synthesis, characterization, DNA interaction studies and anticancer activity of platinum-clotrimazole complexes. Trans Met Chem. 2009;34:869-75.
46. Novakova O, Chen H, Vrana O, Rodger A, Sadler PJ, Brabec V. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. Biochemistry. 2003;42(39):11544-54. (Pubitemid 37205749)
47. Penso J, Beitner R. Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol. 1998;342(1):113-7. (Pubitemid 28131352)
48. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357:1705-15. (Pubitemid 350005152)
49. Qian C, Wang JQ, Song CL, Wang LL, Ji LN, Chao H. The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(ii) asymmetric complexes. Metallomics. 2013;27:844-54.
50. Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole- tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res. 2004;10(11):3717-27. (Pubitemid 38697605)
51. Rajapakse CS, Martinez A, Naoulou B, Jarzecki AA, Suarez L, Deregnaucourt C, et al. Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine. Inorg Chem. 2009;48(3):1122-31.
52. Sanchez-Delgado RA, Anzelloti A, Suarez L. Metal ions and their complexes in medication. In: Siegel H, Siegel A, editors. Metal ions in biological systems. New York: Marcel Dekker; 2004. p. 379.
53. Sanna B, Debidda M, Pintus G, Tadolini B, Posadino AM, Bennardini F, et al. The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide- tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys. 2002;403(2):209-18. (Pubitemid 34800202)
54. Sava G, Capozzi I, Clerici K, Gagliardi G, Alessio E, Mestroni G. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metastasis. 1998;16(4):371-9. (Pubitemid 28255532)
55. Sava G, Bergamo A, Zorzet S, Gava B, Casarsa C, Cocchietto M, et al. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur J Cancer. 2002;38(3):427-35. (Pubitemid 34123316)
56. Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, et al. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem. 2005;48(12):4161-71. (Pubitemid 40803517)
57. Seelig MH, Berger MR, Keppler BK. Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats. J Cancer Res Clin Oncol. 1992;118(3):195-200.
58. Shaik N, Martinez A, Augustin I, Giovinazzo H, Varela-Ramirez A, Sanau M, et al. Synthesis of apoptosis-inducing iminophosphorane organogold(III) complexes and study of their interactions with biomolecular targets. Inorg Chem. 2009;48(4):1577-87.
59. Song L, Li J, Zhang D, Liu ZG, Ye J, Zhan Q, et al. IKKbeta programs to turn on the GADD45alpha-MKK4-JNK apoptotic cascade specifically via p50 NF-kappaB in arsenite response. J Cell Biol. 2006;175:607-17. (Pubitemid 44790614)
60. Soule HD, McGrath CM. A simplified method for passage and long-term growth of human mammary epithelial cells. In Vitro Cell Dev Biol. 1986;22:6-12. (Pubitemid 16167954)
61. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim. 1999;35:403-9. (Pubitemid 29380004)
62. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978;21:274-81. (Pubitemid 8283045)
63. Strasberg RM, Anzellotti A, Sanchez-Delgado RA, Rieber M. Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor. Int J Cancer. 2004;112(3):376-84. (Pubitemid 39390600)
64. Sweetman SC. (Ed). Martindale: the complete drug reference. 37th ed. London: Pharmaceutical Press; 2010.
65. Thum T, Borlak J. Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. Br J Pharmacol. 2000;130(8):1745-52. (Pubitemid 30655785)
66. Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Cancer. 2003;98(9):1855-62. (Pubitemid 37310228)
67. Van CE, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24:4991-4997. (Pubitemid 46631401)
68. Varela-Ramirez A, Costanzo M, Carrasco YP, Pannell KH, Aguilera RJ. Cytotoxic effects of two organotin compounds and their mode of inflicting cell death on four mammalian cancer cells. Cell Biol Toxicol. 2011;27(3):159-68.
69. Wang F, Bella J, Parkinson JA, Sadler PJ. Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide. J Biol Inorg Chem. 2005;10(2):147-55. (Pubitemid 40569009)
70. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG. Design of a potent and selective inhibitor of the intermediate-conductance Ca2 + -activated K + channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A. 2000;97:8151-6. (Pubitemid 30460788)
71. Xiao YF, Huang L, Morgan JP. Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells. J Physiol. 1998;508:777-92. (Pubitemid 28220731)
72. Xie YY, Huang HL, Yao JH, Lin GJ, Jiang GB, Liu YJ. DNA-binding, photocleavage, cytotoxicity in vitro, apoptosis and cell cycle arrest studies of symmetric ruthenium(II) complexes. Eur J Med Chem. 2013;63:603-10.
73. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol. 1985; 134:1623-30. (Pubitemid 15130281)